Specifically, ARK1 shSCRM had significantly higher mean BLI intensity (5.9×108±1.7×108) than those injected with ARK1 shAXL cells (5.1×107±1.1×107), indicating higher tumor burden (P=0.0085, Figure 5A). Here, AURKA is linked to neoplasm.